Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 137

1.

The use of antimicrobial susceptibility testing in pediatric cystic fibrosis pulmonary exacerbations.

Cogen JD, Whitlock KB, Gibson RL, Hoffman LR, VanDevanter DR.

J Cyst Fibros. 2019 May 28. pii: S1569-1993(19)30764-7. doi: 10.1016/j.jcf.2019.05.012. [Epub ahead of print]

PMID:
31147301
2.

Chronic Azithromycin Use in Cystic Fibrosis and Risk of Treatment-Emergent Respiratory Pathogens.

Cogen JD, Onchiri F, Emerson J, Gibson RL, Hoffman LR, Nichols DP, Rosenfeld M.

Ann Am Thorac Soc. 2018 Jun;15(6):702-709. doi: 10.1513/AnnalsATS.201801-012OC.

PMID:
29474110
3.

Islet Interleukin-1β Immunoreactivity Is an Early Feature of Cystic Fibrosis That May Contribute to β-Cell Failure.

Hull RL, Gibson RL, McNamara S, Deutsch GH, Fligner CL, Frevert CW, Ramsey BW, Sanda S.

Diabetes Care. 2018 Apr;41(4):823-830. doi: 10.2337/dc17-1387. Epub 2018 Feb 1.

4.

Variation in Cilia Protein Genes and Progression of Lung Disease in Cystic Fibrosis.

Blue E, Louie TL, Chong JX, Hebbring SJ, Barnes KC, Rafaels NM, Knowles MR, Gibson RL, Bamshad MJ, Emond MJ; U.S. National Heart, Lung, and Blood Institute “Grand Opportunity” Exome Sequencing Project (LungGO).

Ann Am Thorac Soc. 2018 Apr;15(4):440-448. doi: 10.1513/AnnalsATS.201706-451OC.

5.

Airway microbiota across age and disease spectrum in cystic fibrosis.

Zemanick ET, Wagner BD, Robertson CE, Ahrens RC, Chmiel JF, Clancy JP, Gibson RL, Harris WT, Kurland G, Laguna TA, McColley SA, McCoy K, Retsch-Bogart G, Sobush KT, Zeitlin PL, Stevens MJ, Accurso FJ, Sagel SD, Harris JK.

Eur Respir J. 2017 Nov 16;50(5). pii: 1700832. doi: 10.1183/13993003.00832-2017. Print 2017 Nov.

6.

Longitudinal development of initial, chronic and mucoid Pseudomonas aeruginosa infection in young children with cystic fibrosis.

Heltshe SL, Khan U, Beckett V, Baines A, Emerson J, Sanders DB, Gibson RL, Morgan W, Rosenfeld M.

J Cyst Fibros. 2018 May;17(3):341-347. doi: 10.1016/j.jcf.2017.10.008. Epub 2017 Oct 28.

7.

Effect of extending the time after bronchodilator administration on identifying bronchodilator responsiveness in a pediatric pulmonary clinic.

Cogen JD, DiBlasi RM, Gibson RL, Debley JS.

Pediatr Pulmonol. 2017 Aug;52(8):984-989. doi: 10.1002/ppul.23752. Epub 2017 Jul 3.

PMID:
28672068
8.

Home Monitoring of Patients with Cystic Fibrosis to Identify and Treat Acute Pulmonary Exacerbations. eICE Study Results.

Lechtzin N, Mayer-Hamblett N, West NE, Allgood S, Wilhelm E, Khan U, Aitken ML, Ramsey BW, Boyle MP, Mogayzel PJ Jr, Gibson RL, Orenstein D, Milla C, Clancy JP, Antony V, Goss CH; eICE Study Team.

Am J Respir Crit Care Med. 2017 Nov 1;196(9):1144-1151. doi: 10.1164/rccm.201610-2172OC.

9.

Standardized Treatment of Pulmonary Exacerbations (STOP) study: Observations at the initiation of intravenous antibiotics for cystic fibrosis pulmonary exacerbations.

Sanders DB, Solomon GM, Beckett VV, West NE, Daines CL, Heltshe SL, VanDevanter DR, Spahr JE, Gibson RL, Nick JA, Marshall BC, Flume PA, Goss CH; STOP Study Group.

J Cyst Fibros. 2017 Sep;16(5):592-599. doi: 10.1016/j.jcf.2017.04.005. Epub 2017 Apr 29.

10.

Rationalizing endpoints for prospective studies of pulmonary exacerbation treatment response in cystic fibrosis.

VanDevanter DR, Heltshe SL, Spahr J, Beckett VV, Daines CL, Dasenbrook EC, Gibson RL, Raksha J, Sanders DB, Goss CH, Flume PA; STOP Study Group.

J Cyst Fibros. 2017 Sep;16(5):607-615. doi: 10.1016/j.jcf.2017.04.004. Epub 2017 Apr 21.

11.

Characterization of Inpatient Cystic Fibrosis Pulmonary Exacerbations.

Cogen JD, Oron AP, Gibson RL, Hoffman LR, Kronman MP, Ong T, Rosenfeld M.

Pediatrics. 2017 Feb;139(2). pii: e20162642. doi: 10.1542/peds.2016-2642.

12.

Socioeconomic Status, Smoke Exposure, and Health Outcomes in Young Children With Cystic Fibrosis.

Ong T, Schechter M, Yang J, Peng L, Emerson J, Gibson RL, Morgan W, Rosenfeld M; EPIC Study Group.

Pediatrics. 2017 Feb;139(2). pii: e20162730. doi: 10.1542/peds.2016-2730. Epub 2017 Jan 16.

13.

Molecular Genetics of Cystic Fibrosis Transmembrane Conductance Regulator: Genotype and Phenotype.

Sosnay PR, Raraigh KS, Gibson RL.

Pediatr Clin North Am. 2016 Aug;63(4):585-98. doi: 10.1016/j.pcl.2016.04.002. Review.

PMID:
27469177
14.

Addiction, 12-Step Programs, and Evidentiary Standards for Ethically and Clinically Sound Treatment Recommendations: What Should Clinicians Do?

Mendola A, Gibson RL.

AMA J Ethics. 2016 Jun 1;18(6):646-55. doi: 10.1001/journalofethics.2016.18.6.sect1-1606.

15.

Sinonasal Quality of Life in Children With Cystic Fibrosis.

Chan DK, McNamara S, Park JS, Vajda J, Gibson RL, Parikh SR.

JAMA Otolaryngol Head Neck Surg. 2016 Aug 1;142(8):743-9. doi: 10.1001/jamaoto.2016.0979.

PMID:
27228505
16.

US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis: executive summary.

Floto RA, Olivier KN, Saiman L, Daley CL, Herrmann JL, Nick JA, Noone PG, Bilton D, Corris P, Gibson RL, Hempstead SE, Koetz K, Sabadosa KA, Sermet-Gaudelus I, Smyth AR, van Ingen J, Wallace RJ, Winthrop KL, Marshall BC, Haworth CS.

Thorax. 2016 Jan;71(1):88-90. doi: 10.1136/thoraxjnl-2015-207983.

17.

US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis.

Floto RA, Olivier KN, Saiman L, Daley CL, Herrmann JL, Nick JA, Noone PG, Bilton D, Corris P, Gibson RL, Hempstead SE, Koetz K, Sabadosa KA, Sermet-Gaudelus I, Smyth AR, van Ingen J, Wallace RJ, Winthrop KL, Marshall BC, Haworth CS; US Cystic Fibrosis Foundation and European Cystic Fibrosis Society.

Thorax. 2016 Jan;71 Suppl 1:i1-22. doi: 10.1136/thoraxjnl-2015-207360.

18.

Early Childhood Risk Factors for Decreased FEV1 at Age Six to Seven Years in Young Children with Cystic Fibrosis.

Sanders DB, Emerson J, Ren CL, Schechter MS, Gibson RL, Morgan W, Rosenfeld M; EPIC Study Group.

Ann Am Thorac Soc. 2015 Aug;12(8):1170-6. doi: 10.1513/AnnalsATS.201504-198OC.

19.

Correction: Exome Sequencing of Phenotypic Extremes Identifies CAV2 and TMC6 as Interacting Modifiers of Chronic Pseudomonas aeruginosa Infection in Cystic Fibrosis.

Emond MJ, Louie T, Emerson J, Chong JX, Mathias RA, Knowles MR, Rieder MJ, Tabor HK, Nickerson DA, Barnes KC; NHLBI GO Exome Sequencing Project, Go L, Gibson RL, Bamshad MJ.

PLoS Genet. 2015 Aug 18;11(8):e1005424. doi: 10.1371/journal.pgen.1005424. eCollection 2015 Aug. No abstract available.

20.

Risk factors for lung function decline in a large cohort of young cystic fibrosis patients.

Cogen J, Emerson J, Sanders DB, Ren C, Schechter MS, Gibson RL, Morgan W, Rosenfeld M; EPIC Study Group.

Pediatr Pulmonol. 2015 Aug;50(8):763-70. doi: 10.1002/ppul.23217. Epub 2015 Jun 9.

21.

Exome Sequencing of Phenotypic Extremes Identifies CAV2 and TMC6 as Interacting Modifiers of Chronic Pseudomonas aeruginosa Infection in Cystic Fibrosis.

Emond MJ, Louie T, Emerson J, Chong JX, Mathias RA, Knowles MR, Rieder MJ, Tabor HK, Nickerson DA, Barnes KC; NHLBI GO Exome Sequencing Project, Go L, Gibson RL, Bamshad MJ.

PLoS Genet. 2015 Jun 5;11(6):e1005273. doi: 10.1371/journal.pgen.1005273. eCollection 2015 Jun. Erratum in: PLoS Genet. 2015 Aug;11(8):e1005424.

22.

Impact of Sustained Eradication of New Pseudomonas aeruginosa Infection on Long-term Outcomes in Cystic Fibrosis.

Mayer-Hamblett N, Kloster M, Rosenfeld M, Gibson RL, Retsch-Bogart GZ, Emerson J, Thompson V, Ramsey BW.

Clin Infect Dis. 2015 Sep 1;61(5):707-15. doi: 10.1093/cid/civ377. Epub 2015 May 13.

23.

Serology as a diagnostic tool for predicting initialPseudomonas aeruginosa acquisition in children with cystic fibrosis.

Daines C, VanDeVanter D, Khan U, Emerson J, Heltshe S, McNamara S, Anstead M, Langkamp M, Doring G, Ratjen F, Ramsey B, Gibson RL, Morgan W, Rosenfeld M; EPIC Investigators.

J Cyst Fibros. 2014 Sep;13(5):542-9. doi: 10.1016/j.jcf.2014.06.005. Epub 2014 Jul 11.

24.

Pseudomonas aeruginosa in vitro phenotypes distinguish cystic fibrosis infection stages and outcomes.

Mayer-Hamblett N, Rosenfeld M, Gibson RL, Ramsey BW, Kulasekara HD, Retsch-Bogart GZ, Morgan W, Wolter DJ, Pope CE, Houston LS, Kulasekara BR, Khan U, Burns JL, Miller SI, Hoffman LR.

Am J Respir Crit Care Med. 2014 Aug 1;190(3):289-97. doi: 10.1164/rccm.201404-0681OC.

25.

Pseudomonas aeruginosa phenotypes associated with eradication failure in children with cystic fibrosis.

Mayer-Hamblett N, Ramsey BW, Kulasekara HD, Wolter DJ, Houston LS, Pope CE, Kulasekara BR, Armbruster CR, Burns JL, Retsch-Bogart G, Rosenfeld M, Gibson RL, Miller SI, Khan U, Hoffman LR.

Clin Infect Dis. 2014 Sep 1;59(5):624-31. doi: 10.1093/cid/ciu385. Epub 2014 May 26.

26.

Clinical outcomes after initial pseudomonas acquisition in cystic fibrosis.

Zemanick ET, Emerson J, Thompson V, McNamara S, Morgan W, Gibson RL, Rosenfeld M; EPIC Study Group.

Pediatr Pulmonol. 2015 Jan;50(1):42-8. doi: 10.1002/ppul.23036. Epub 2014 Mar 18.

PMID:
24644274
27.

Home Self-Collection of Nasal Swabs for Diagnosis of Acute Respiratory Virus Infections in Children With Cystic Fibrosis.

Emerson J, Cochrane E, McNamara S, Kuypers J, Gibson RL, Campbell AP.

J Pediatric Infect Dis Soc. 2013 Dec;2(4):345-51. doi: 10.1093/jpids/pit039. Epub 2013 Jul 14.

28.

Standard care versus protocol based therapy for new onset Pseudomonas aeruginosa in cystic fibrosis.

Mayer-Hamblett N, Rosenfeld M, Treggiari MM, Konstan MW, Retsch-Bogart G, Morgan W, Wagener J, Gibson RL, Khan U, Emerson J, Thompson V, Elkin EP, Ramsey BW; EPIC; ESCF Investigators.

Pediatr Pulmonol. 2013 Oct;48(10):943-53. doi: 10.1002/ppul.22693. Epub 2013 Jul 2.

29.

Staphylococcus aureus small-colony variants are independently associated with worse lung disease in children with cystic fibrosis.

Wolter DJ, Emerson JC, McNamara S, Buccat AM, Qin X, Cochrane E, Houston LS, Rogers GB, Marsh P, Prehar K, Pope CE, Blackledge M, Déziel E, Bruce KD, Ramsey BW, Gibson RL, Burns JL, Hoffman LR.

Clin Infect Dis. 2013 Aug;57(3):384-91. doi: 10.1093/cid/cit270. Epub 2013 Apr 26.

30.

Pseudomonas aeruginosa serology and risk for re-isolation in the EPIC trial.

Anstead M, Heltshe SL, Khan U, Barbieri JT, Langkamp M, Döring G, Dharia S, Gibson RL, Treggiari MM, Lymp J, Rosenfeld M, Ramsey B.

J Cyst Fibros. 2013 Mar;12(2):147-53. doi: 10.1016/j.jcf.2012.08.001. Epub 2012 Sep 1.

31.

Exome sequencing of extreme phenotypes identifies DCTN4 as a modifier of chronic Pseudomonas aeruginosa infection in cystic fibrosis.

Emond MJ, Louie T, Emerson J, Zhao W, Mathias RA, Knowles MR, Wright FA, Rieder MJ, Tabor HK, Nickerson DA, Barnes KC; National Heart, Lung, and Blood Institute (NHLBI) GO Exome Sequencing Project; Lung GO, Gibson RL, Bamshad MJ.

Nat Genet. 2012 Jul 8;44(8):886-9. doi: 10.1038/ng.2344.

32.

Detection of DNA damage in workers exposed to JP-8 jet fuel.

Krieg EF Jr, Mathias PI, Toennis CA, Clark JC, Marlow KL, B'hymer C, Singh NP, Gibson RL, Butler MA.

Mutat Res. 2012 Sep 18;747(2):218-27. doi: 10.1016/j.mrgentox.2012.05.005. Epub 2012 May 19.

PMID:
22617435
33.

Risk factors for age at initial Pseudomonas acquisition in the cystic fibrosis epic observational cohort.

Rosenfeld M, Emerson J, McNamara S, Thompson V, Ramsey BW, Morgan W, Gibson RL; EPIC Study Group.

J Cyst Fibros. 2012 Sep;11(5):446-53. doi: 10.1016/j.jcf.2012.04.003. Epub 2012 May 1.

34.

Feasibility of using pedometers to measure daily step counts in cystic fibrosis and an assessment of its responsiveness to changes in health state.

Quon BS, Patrick DL, Edwards TC, Aitken ML, Gibson RL, Genatossio A, McNamara S, Goss CH.

J Cyst Fibros. 2012 May;11(3):216-22. doi: 10.1016/j.jcf.2011.12.002. Epub 2012 Jan 4.

35.

Viruses and vitamin D in the etiology of type 1 diabetes mellitus and multiple sclerosis.

Jankosky C, Deussing E, Gibson RL, Haverkos HW.

Virus Res. 2012 Feb;163(2):424-30. doi: 10.1016/j.virusres.2011.11.010. Epub 2011 Nov 20. Review.

PMID:
22119899
36.

Respiratory viruses in children with cystic fibrosis: viral detection and clinical findings.

Burns JL, Emerson J, Kuypers J, Campbell AP, Gibson RL, McNamara S, Worrell K, Englund JA.

Influenza Other Respir Viruses. 2012 May;6(3):218-23. doi: 10.1111/j.1750-2659.2011.00292.x. Epub 2011 Sep 29.

37.

Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis.

Treggiari MM, Retsch-Bogart G, Mayer-Hamblett N, Khan U, Kulich M, Kronmal R, Williams J, Hiatt P, Gibson RL, Spencer T, Orenstein D, Chatfield BA, Froh DK, Burns JL, Rosenfeld M, Ramsey BW; Early Pseudomonas Infection Control (EPIC) Investigators.

Arch Pediatr Adolesc Med. 2011 Sep;165(9):847-56. doi: 10.1001/archpediatrics.2011.136.

38.

Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis.

Mayer-Hamblett N, Kronmal RA, Gibson RL, Rosenfeld M, Retsch-Bogart G, Treggiari MM, Burns JL, Khan U, Ramsey BW; EPIC Investigators.

Pediatr Pulmonol. 2012 Feb;47(2):125-34. doi: 10.1002/ppul.21525. Epub 2011 Aug 9.

39.

(2-methoxyethoxy)acetic acid: a urinary biomarker of exposure for jet fuel JP-8.

B'hymer C, Mathias P, Krieg E Jr, Cheever KL, Toennis CA, Clark JC, Kesner JS, Gibson RL, Butler MA.

Int Arch Occup Environ Health. 2012 May;85(4):413-20. doi: 10.1007/s00420-011-0687-7. Epub 2011 Aug 2.

PMID:
21809101
40.

Pseudomonas aeruginosa antibiotic susceptibility during long-term use of aztreonam for inhalation solution (AZLI).

Oermann CM, McCoy KS, Retsch-Bogart GZ, Gibson RL, McKevitt M, Montgomery AB.

J Antimicrob Chemother. 2011 Oct;66(10):2398-404. doi: 10.1093/jac/dkr303. Epub 2011 Jul 22.

PMID:
21784781
41.

Aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis, mild lung impairment, and P. aeruginosa.

Wainwright CE, Quittner AL, Geller DE, Nakamura C, Wooldridge JL, Gibson RL, Lewis S, Montgomery AB.

J Cyst Fibros. 2011 Jul;10(4):234-42. doi: 10.1016/j.jcf.2011.02.007. Epub 2011 Mar 26.

42.

Randomized trial of biofilm testing to select antibiotics for cystic fibrosis airway infection.

Moskowitz SM, Emerson JC, McNamara S, Shell RD, Orenstein DM, Rosenbluth D, Katz MF, Ahrens R, Hornick D, Joseph PM, Gibson RL, Aitken ML, Benton WW, Burns JL.

Pediatr Pulmonol. 2011 Feb;46(2):184-92. doi: 10.1002/ppul.21350. Epub 2010 Oct 20.

43.

An 18-month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis.

Oermann CM, Retsch-Bogart GZ, Quittner AL, Gibson RL, McCoy KS, Montgomery AB, Cooper PJ.

Pediatr Pulmonol. 2010 Nov;45(11):1121-34. doi: 10.1002/ppul.21301.

44.

Baseline characteristics and factors associated with nutritional and pulmonary status at enrollment in the cystic fibrosis EPIC observational cohort.

Rosenfeld M, Emerson J, McNamara S, Joubran K, Retsch-Bogart G, Graff GR, Gutierrez HH, Kanga JF, Lahiri T, Noyes B, Ramsey B, Ren CL, Schechter M, Morgan W, Gibson RL; EPIC Study Group Participating Clinical Sites.

Pediatr Pulmonol. 2010 Sep;45(9):934-44. doi: 10.1002/ppul.21279.

PMID:
20597081
45.

Return of FEV1 after pulmonary exacerbation in children with cystic fibrosis.

Sanders DB, Hoffman LR, Emerson J, Gibson RL, Rosenfeld M, Redding GJ, Goss CH.

Pediatr Pulmonol. 2010 Feb;45(2):127-34. doi: 10.1002/ppul.21117. Erratum in: Pediatr Pulmonol. 2010 May;45(5):521-2.

PMID:
20054859
46.

Early anti-pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'.

Treggiari MM, Rosenfeld M, Mayer-Hamblett N, Retsch-Bogart G, Gibson RL, Williams J, Emerson J, Kronmal RA, Ramsey BW; EPIC Study Group.

Contemp Clin Trials. 2009 May;30(3):256-68. doi: 10.1016/j.cct.2009.01.003. Epub 2009 Jan 15.

47.

Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis.

Retsch-Bogart GZ, Quittner AL, Gibson RL, Oermann CM, McCoy KS, Montgomery AB, Cooper PJ.

Chest. 2009 May;135(5):1223-1232. doi: 10.1378/chest.08-1421.

48.

Oral manifestations associated with focal dermal hypoplasia.

Seoane J, Gibson RL, Almagro M, Pintos E.

Dermatology. 2009;219(4):368-70. doi: 10.1159/000210171. Epub 2009 Mar 26. No abstract available.

PMID:
19321948
49.

Clinical practice and genetic counseling for cystic fibrosis and CFTR-related disorders.

Moskowitz SM, Chmiel JF, Sternen DL, Cheng E, Gibson RL, Marshall SG, Cutting GR.

Genet Med. 2008 Dec;10(12):851-68. doi: 10.1097/GIM.0b013e31818e55a2. Review.

50.

Impact of Pseudomonas and Staphylococcus infection on inflammation and clinical status in young children with cystic fibrosis.

Sagel SD, Gibson RL, Emerson J, McNamara S, Burns JL, Wagener JS, Ramsey BW; Inhaled Tobramycin in Young Children Study Group; Cystic Fibrosis Foundation Therapeutics Development Network.

J Pediatr. 2009 Feb;154(2):183-8. doi: 10.1016/j.jpeds.2008.08.001. Epub 2008 Sep 25.

Supplemental Content

Loading ...
Support Center